Growing pains for biopharmaceuticals

被引：9

作者：

Ashton, G ^{[1
]}

机构：

[1] Ctr Med Res Int, Surrey, England

来源：

NATURE BIOTECHNOLOGY | 2001年 / 19卷 / 04期

关键词：

Industrial economics - Industrial management - Pipelines;

D O I：

10.1038/86670

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Biopharmaceuticals have provided a swift means of swelling pharmaceutical company pipelines, but they may not be such a fast "fix" for the industry in the future.

引用

页码：307 / 311

页数：5

共 15 条

[1]

AITKEN M, 1999, WINNING PHARM LICENS, P49

[2] BIOPHARMACEUTICALS AND CONVENTIONAL DRUGS - CLINICAL SUCCESS RATES [J].

BIENZTADMOR, B ;

DICERBO, PA ;

TADMOR, G ;

LASAGNA, L .

BIO-TECHNOLOGY, 1992, 10 (05) :521-525

[3]

GRONER C, 1999, BIOPEOPLE AUT, P26

[4]

GROSSE ME, 1996, DRUG INF J, V30, P991

[5] Not quite pharmacogenomics [J].

Haseltine, WA .

NATURE BIOTECHNOLOGY, 1998, 16 (13) :1295-1295

[6]

HENKEL J, 1999, FDA CONSUMER MAGAZIN, V33

[7]

HODGE MJ, 1997, EC ASPECTS BIOTECH 1, P219

[8]

Kettler H, 2000, JCB, V7, P62

[9]

LOBO LI, 2000, CMR00146R

[10]

MACINNES R, 1994, CLIN PHARMACOL THER, V56, P339

← 1 2 →